The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels

被引:0
|
作者
Kerb R. [1 ]
Aynacioglu A.S. [2 ,3 ]
Brockmöller J. [2 ]
Schlagenhaufer R. [1 ]
Bauer S. [2 ]
Szekeres T. [4 ]
Hamwi A. [4 ]
Fritzer-Szekeres M. [4 ]
Baumgartner C. [5 ]
Öngen H.Z. [6 ]
Güzelbey P. [6 ]
Roots I. [2 ]
Brinkmann U. [1 ]
机构
[1] Epidauros Biotechnology AG, Pharmacogenetics Laboratory, Bernried
[2] Institute of Clinical Pharmacology, University Medical Center Charité, Humboldt University, Berlin
[3] Department of Pharmacology, Medical Faculty, Pamukkale University, Denizli
[4] Institute of Clinical Chemistry, AKH-Wien, University of Vienna, Vienna
[5] Institute of Neurology, AKHWien, University of Vienna, Vienna
[6] Department of Pharmacology, University of Gaziantep
关键词
Pharmacogenetlcs; Polymorphism; TDM;
D O I
10.1038/sj.tpj.6500025
中图分类号
学科分类号
摘要
Phenytoin, an anticonvulsant, exhibits nonlinear pharmacokinetics with large interindividual differences. Because of its small therapeutic range with the risk of therapeutic failure or adverse drug effects in susceptible persons, therapeutic drug monitoring is frequently applied. The interindividual differences in dose response can partially be explained by known genetic polymorphisms in the metabolic enzyme CYP2C9 but a large deal of individual variability remains still unexplained. Part of this variability might be accounted for by variable uptake of phenytoin, which is a substrate of p-glycoprotein, encoded by the human MDR1 gene. We evaluated, whether phenytoin plasma levels correlate with a polymorphism in the MDR1 gene, C3435T, which is associated with intestinal PCP activity. Genotyping and analyses of plasma levels of phenytoin and metabolites in 96 healthy Turkish volunteers showed that the MDR1C > T3435 polymorphism affects phenytoin plasma levels (P = 0.064) and the metabolic ratio of p-HPPH vs phenytoin (MDR1*TT genotype, P = 0.026). The MDR1*CC genotype is more common in volunteers with low phenytoin levels (P ≤ 0.001, χ2 test). A combined analysis of variable alleles of CYP2C9, 2C19 and MDR1 revealed that the number of mutant CYP2C9 alleles is a major determinant, the number of MDR1*T alleles further contributes to the prediction of phenytoin plasma levels and CYP2C19*2 does not explain individual variability. The regression equation that fitted the data best included the number of mutant CYP2C9 and MDR*T alleles as predictory variables and explained 15.4% of the variability of phenytoin data (r2 = 0.154, P = 0.0002). Furthermore, analysis of CYP2C9 and MDR1 genotypes in 35 phenytoin-treated patients recruited from therapeutic drug monitoring showed that combined CYP2C9 and MDR1 analysis has some predictive value not only in the controlled settings of a clinical trial, but also in the daily clinical practice. © 2001 Nature Publishing Group All rights reserved.
引用
收藏
页码:204 / 210
页数:6
相关论文
共 50 条
  • [1] CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population
    Allabi, AC
    Gala, JL
    Horsmans, Y
    PHARMACOGENETICS AND GENOMICS, 2005, 15 (11): : 779 - 786
  • [2] Dosage recommendation of phenytoin for patients with epilepsy with different CYP2C9/CYP2C19 polymorphisms
    Hung, CC
    Lin, CJ
    Chen, CC
    Chang, CJ
    Liou, HH
    THERAPEUTIC DRUG MONITORING, 2004, 26 (05) : 534 - 540
  • [3] Genetic polymorphisms of CYP20, CYP2C19 and MDR1 genes and their effect on phenytoin disposition
    Bozina, N
    Granic, P
    Hajnsek, S
    Lalic, Z
    Basic, S
    Lovric, M
    Stavljenic-Rukavina, A
    PERIODICUM BIOLOGORUM, 2005, 107 (02) : 183 - 187
  • [4] Effects of mutations in CYP2C9 and CYP2C19 genes on phenytoin dose
    Kijsanayotin, Pornpimol
    Cloyd, James C.
    Leppik, Ilo E.
    Birnbaum, Angela K.
    Prassitisopin, Baralee
    Ramsay, R. Eugene
    Rarick, John O.
    Mishra, Usha
    White, James R.
    Marino, Susan E.
    Conway, Jeannine M.
    Oetting, William S.
    NEUROLOGY, 2007, 68 (12) : A212 - A212
  • [5] A meta-analysis of effects of CYP2C9 and CYP2C19 polymorphisms on phenytoin pharmacokinetic parameters
    Kanjanasilp, Juntip
    Sawangjit, Ratree
    Phanthaisong, Sirikhwan
    Borihanthanawuth, Wongvaruth
    PHARMACOGENOMICS, 2021, 22 (10) : 629 - 640
  • [6] Role of CYP2C9 and CYP2C19 polymorphisms in patients with atherosclerosis
    Ercan, B.
    Ayaz, L.
    Cicek, D.
    Tamer, L.
    CELL BIOCHEMISTRY AND FUNCTION, 2008, 26 (03) : 309 - 313
  • [7] CYP2C9, CYP2C19, and ABCB1 Genotype and Hospitalization for Phenytoin Toxicity
    Hennessy, Sean
    Leonard, Charles E.
    Freeman, Cristin P.
    Metlay, Joshua P.
    Chu, Xin
    Strom, Brian L.
    Bilker, Warren B.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 49 (12): : 1483 - 1487
  • [8] Distribution of polymorphisms in the CYP2C9 gene and CYP2C19/CYP2C9 haplotypes among Venezuelan populations
    Flores-Gutierrez, Sara
    Rodriguez-Larralde, Alvaro
    Vivenes de Lugo, Merlyn
    Castro de Guerra, Dinorah
    ANNALS OF HUMAN BIOLOGY, 2017, 44 (02) : 191 - 198
  • [9] CYP2C9, CYP2C19 and ABCB1 Genotype and Hospitalization for Phenytoin Toxicity
    Hennessy, Sean
    Leonard, Charles E.
    Palumbo, Cristin M.
    Metlay, Joshua P.
    Chu, Xin
    Strom, Brian L.
    Bilker, Warren B.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2009, 18 : S22 - S22
  • [10] Influence of the CYP2C9 & CYP2C19 polymorphisms on phenytoin hydroxylation in healthy individuals from south India
    Rosemary, J.
    Surendiran, A.
    Rajan, S.
    Shashindran, C. H.
    Adithan, C.
    INDIAN JOURNAL OF MEDICAL RESEARCH, 2006, 123 (05) : 665 - 670